InvestorPlace – Stock Market News, Stock Advice & Trading Tips
Biotech stocks, namely those involved with gene editing, have been explosive.
Just look at CRISPR Therapeutics (NASADQ:CRSP), for example. Since late October, CRSP rocketed from about $40 a share to about $90.18. All thanks to positive US FDA and European Commission rulings on CRISPR’s treatments for sickle cell, and transfusion-dependent beta-thalassemia.
Even shares of Beam Therapeutics (NASDAQ:BEAM)…
Read More…